Methods Explored for Gram-Negative Non-Fermentative Bacteria ID
|
By LabMedica International staff writers Posted on 26 Oct 2019 |

Image: The PHOENIX system is for rapid automated identification and antimicrobial susceptibility testing of clinically relevant microorganisms (Photo courtesy of Becton, Dickinson and Company).
The non-fermentative Gram-negative bacteria are widely distributed in the environment and have become increasingly common isolates in the clinical laboratory. Being ubiquitous in nature, they are often disregarded as contaminants.
This group of non-fermentative Gram-negative bacteria has emerged as opportunistic pathogens, particularly in immunocompromised hosts, and is difficult to treat because of widespread antibiotic resistance. Due to their taxonomic complexity and phenotypic similarity accurate identification represents a challenge for conventional microbiology.
Scientists from the Centers for Disease Control and Prevention (Atlanta, GA, USA) working with their colleagues in Thailand used unidentified Gram negative bacterial isolates that were collected during 2006–2014 as part of a previously published surveillance system. Organisms were taken from the isolate culture collections of the Sa Kaeo and Nakhon Phanom Provincial Health Laboratories that had been previously been characterized using standard biochemical testing methods.
A subset of gram negative non-fermentative (GNNF) clinical isolates (204/947), not identified by standard manual biochemical methodologies were run on the BD Phoenix automated identification and susceptibility testing system. If an organism was not identified (12/204) DNA was extracted for whole genome sequencing (WGS) on a MiSeq platform and data analysis performed using three web-based platforms: Taxonomer, CGE KmerFinder and One Codex. Isolates were grown on tryptic soy agar with 5% sheep blood.
The team reported that the BD Phoenix automated identification system recognized 92% (187/204) of the GNNF isolates, and because of their taxonomic complexity and high phenotypic similarity 37% (69/187) were only identified to the genus level. The largest number of isolates identified as Achromobacter species (46/204; 22.5%), with nearly 70% of cases being in adults ≥50 years of age. Antimicrobial sensitivity (AST) data was not obtained for 93/187 (50%) identified isolates either because of their slow growth or their taxa were not in the AST database associated with the instrument. WGS identified the 12 remaining unknowns, four to genus level only.
Pseudomonas species were identified in 35/204 isolates (17.2%) of which the most common were P. putida (11; 31.4%), and P. pseudoalcaligenes eight (22.9%). P. oryzihabitans and P. aeruginosa had five and four isolates respectively, and an isolation each of P. luteola, P. mendocina and P. stutzeri. The third most common isolates were Moraxella species (14/204 cases (6.9%)), with five being hospital onset infections.
The authors concluded that GNNF bacteria are of increasing concern in the clinical setting, and the inability to identify these organisms and determine their AST profiles will impede treatment. Databases for automated identification systems and sequencing annotation need to be improved so that opportunistic organisms are better covered. The study was published on September 30, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Centers for Disease Control and Prevention
This group of non-fermentative Gram-negative bacteria has emerged as opportunistic pathogens, particularly in immunocompromised hosts, and is difficult to treat because of widespread antibiotic resistance. Due to their taxonomic complexity and phenotypic similarity accurate identification represents a challenge for conventional microbiology.
Scientists from the Centers for Disease Control and Prevention (Atlanta, GA, USA) working with their colleagues in Thailand used unidentified Gram negative bacterial isolates that were collected during 2006–2014 as part of a previously published surveillance system. Organisms were taken from the isolate culture collections of the Sa Kaeo and Nakhon Phanom Provincial Health Laboratories that had been previously been characterized using standard biochemical testing methods.
A subset of gram negative non-fermentative (GNNF) clinical isolates (204/947), not identified by standard manual biochemical methodologies were run on the BD Phoenix automated identification and susceptibility testing system. If an organism was not identified (12/204) DNA was extracted for whole genome sequencing (WGS) on a MiSeq platform and data analysis performed using three web-based platforms: Taxonomer, CGE KmerFinder and One Codex. Isolates were grown on tryptic soy agar with 5% sheep blood.
The team reported that the BD Phoenix automated identification system recognized 92% (187/204) of the GNNF isolates, and because of their taxonomic complexity and high phenotypic similarity 37% (69/187) were only identified to the genus level. The largest number of isolates identified as Achromobacter species (46/204; 22.5%), with nearly 70% of cases being in adults ≥50 years of age. Antimicrobial sensitivity (AST) data was not obtained for 93/187 (50%) identified isolates either because of their slow growth or their taxa were not in the AST database associated with the instrument. WGS identified the 12 remaining unknowns, four to genus level only.
Pseudomonas species were identified in 35/204 isolates (17.2%) of which the most common were P. putida (11; 31.4%), and P. pseudoalcaligenes eight (22.9%). P. oryzihabitans and P. aeruginosa had five and four isolates respectively, and an isolation each of P. luteola, P. mendocina and P. stutzeri. The third most common isolates were Moraxella species (14/204 cases (6.9%)), with five being hospital onset infections.
The authors concluded that GNNF bacteria are of increasing concern in the clinical setting, and the inability to identify these organisms and determine their AST profiles will impede treatment. Databases for automated identification systems and sequencing annotation need to be improved so that opportunistic organisms are better covered. The study was published on September 30, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Centers for Disease Control and Prevention
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







